<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Prev Med</journal-id><journal-id journal-id-type="iso-abbrev">Am J Prev Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>American journal of preventive medicine</journal-title></journal-title-group><issn pub-type="ppub">0749-3797</issn><issn pub-type="epub">1873-2607</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10121731</article-id><article-id pub-id-type="pmcid-ver">PMC10121731.1</article-id><article-id pub-id-type="pmcaid">10121731</article-id><article-id pub-id-type="pmcaiid">10121731</article-id><article-id pub-id-type="manuscript-id">NIHMS1866084</article-id><article-id pub-id-type="pmid">36759228</article-id><article-id pub-id-type="doi">10.1016/j.amepre.2023.01.005</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1866084</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1866084</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>HCV Testing and Care Cascade among Transgender and Gender Diverse Individuals</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wolfe</surname><given-names initials="HL">Hill L.</given-names></name><degrees>PhD, MPA</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hughto</surname><given-names initials="JMW">Jaclyn M.W.</given-names></name><degrees>PhD, MPH</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quint</surname><given-names initials="M">Meg</given-names></name><degrees>BS</degrees><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hashemi</surname><given-names initials="L">Leila</given-names></name><degrees>MD</degrees><xref rid="A7" ref-type="aff">7</xref><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hughes</surname><given-names initials="LD">Landon D.</given-names></name><degrees>BA</degrees><xref rid="A9" ref-type="aff">9</xref><xref rid="A10" ref-type="aff">10</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, MA, USA;</aff><aff id="A2"><label>2</label>Center for Health Promotion and Health Equity, Brown University School of Public Health, Providence, RI, USA;</aff><aff id="A3"><label>3</label>Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA;</aff><aff id="A4"><label>4</label>Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA;</aff><aff id="A5"><label>5</label>The Fenway Institute, Fenway Health, Boston, MA, USA;</aff><aff id="A6"><label>6</label>Division of Endocrinology, Diabetes and Hypertension, Brigham and Women&#8217;s Hospital, Boston, MA, USA;</aff><aff id="A7"><label>7</label>VA Greater Los Angeles Healthcare System, Department of General Internal Medicine, Los Angeles, CA, USA;</aff><aff id="A8"><label>8</label>David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA;</aff><aff id="A9"><label>9</label>Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, USA;</aff><aff id="A10"><label>10</label>Institute for Social Research, University of Michigan, Ann Arbor, MI, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding author:</bold> Hill L. Wolfe, Department of Health Law, Policy and Management, Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, Phone: (857) 600-1256; <email>hlw64@bu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2023</year></pub-date><issue-id pub-id-type="pmc-issue-id">434055</issue-id><elocation-id>S0749-3797(23)00007-7</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>19</day><month>01</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 11:25:31.053"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1866084.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">Hepatitis C virus (HCV) prevalence among transgender and gender diverse (TGD) individuals ranges from 1.8%&#8722;15.7% vs. 1% in the general population. Prior HCV studies inclusive of TGD individuals primarily rely on convenience-based sampling methods or are geographically restricted. The purpose of this study is to compare the prevalence of HCV diagnoses, testing, and care engagement between TGD and cisgender individuals.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">Using Optum&#8217;s de-identified Clinformatics<sup>&#174;</sup> Data Mart Database, in 2022, the unadjusted prevalence of HCV testing among all adults and people who inject drugs (PWID) from January 2001 to December 2019 was measured. Multivariable logistic regression was used to compare the adjusted odds of HCV diagnoses and care engagement by gender subgroup.</p></sec><sec id="S3"><title>Results:</title><p id="P3">The overall unadjusted frequency of HCV diagnoses among TGD individuals was approximately 3 times that of cisgender individuals (1.06% vs. 0.38%, <italic toggle="yes">p</italic>&lt;0.001), including among PWID (6.36% vs. 2.36%, <italic toggle="yes">p</italic>=0.007). Compared to cisgender women, trans feminine/non-binary individuals had over 5 times the adjusted odds of an HCV diagnosis and approximately 3.5 times the odds of being tested for HCV. Additionally, compared to cisgender women, trans feminine/non-binary individuals had significantly increased odds of having an HCV-related procedure (e.g., abdominal ultrasounds, liver biopsies, Fibroscans). Cisgender men had significantly increased odds of receiving HCV medication compared to cisgender women.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">While testing was higher among TGD individuals, the higher overall frequency of HCV diagnoses among TGD vs. cisgender individuals signal persistent health disparities. Interventions are warranted to prevent HCV and increase ongoing testing and treatment uptake among TGD populations.</p></sec></abstract><kwd-group><kwd>transgender and gender diverse</kwd><kwd>hepatitis C</kwd><kwd>injection drug use</kwd><kwd>HCV testing</kwd><kwd>HCV care cascade</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>